Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 244

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 244
---
 | 2020-2022: 0%     | 2020-2022: 86.94%i.e. 65,205 performanceshares |
| April 30, 2021 plans | 2021-2023: 103.58% | 2021-2023: 110.31% | 2021-2023: 51.77% | 2021-2023: 95.23%i.e. 71,423performanceshares  |
| May 3, 2022 plans    | 2022-2024: 102.56% | 2022-2024: 110.25% | 2022-2024: 0%     | 2022-2024:84.36%i.e.69,597 performanceshares   |

| SANOFIFORM 20-F2024 | 143 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Performance shares awarded to Paul Hudson in 2024 (table No. 6 of the AFEP-MEDEF Code)

| Source | Plan date  | Valuation ofperformance shares(€) | Number of performanceshares awardedduring the period | Vestingdate | Availabilitydate(a) | Performanceconditions |
| Sanofi | 04/30/2024 |                         5,971,350 |                                               82,500 | 04/30/2027  | 04/30/2027          | Yes                   |

(a) Under the terms of our Board Charter, Paul Hudson is required to retain a quantity of shares corresponding to 50% of the capital gain arising on the vesting of the shares, net of the associated taxes and social contributions. Each performance share awarded on April 30 , 2024, was valued at €72.38, valuing the total benefit at €5,971,350. The General Meeting of April 30, 2024 restricted the number of performance shares that can be awarded to executive officers to 5% of the overall limit (itself set at 1.5% of the share capital). The number of shares awarded to Paul Hudson in 2024 r epresent s 0.43% of the total limit approved by that Meeting and 0.006% of our share capital at the date of grant. Performance shares awarded to Paul Hudson which became available in 2024 (table No. 7 of the